Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.
Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M, Vosburgh E. Comenzo RL, et al. Among authors: berk jl. Br J Haematol. 1999 Mar;104(3):553-9. doi: 10.1046/j.1365-2141.1999.01216.x. Br J Haematol. 1999. PMID: 10086794 Free article. Clinical Trial.
High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. Sanchorawala V, et al. Among authors: berk jl. Bone Marrow Transplant. 2004 Feb;33(4):381-8. doi: 10.1038/sj.bmt.1704346. Bone Marrow Transplant. 2004. PMID: 14676787 Clinical Trial.
High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution.
Seldin DC, Andrea N, Berenbaum I, Berk JL, Connors L, Dember LM, Doros G, Fennessey S, Finn K, Girnius S, Lerner A, Libbey C, Meier-Ewert HK, O'Connell R, O'Hara C, Quillen K, Ruberg FL, Sam F, Segal A, Shelton A, Skinner M, Sloan JM, Wiesman JF, Sanchorawala V. Seldin DC, et al. Among authors: berk jl. Amyloid. 2011 Jun;18 Suppl 1(Suppl 1):127-9. doi: 10.3109/13506129.2011.574354047. Amyloid. 2011. PMID: 21838459 Free PMC article.
The diflunisal trial: update on study drug tolerance and disease progression.
Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, Ando Y, Ikeda SI, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Suhr OB; Familial Amyloidosis Consortium. Berk JL, et al. Amyloid. 2011 Jun;18 Suppl 1:196-7. doi: 10.3109/13506129.2011.574354073. Amyloid. 2011. PMID: 21838485 No abstract available.
Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
Brannagan TH, Wang AK, Coelho T, Waddington Cruz M, Polydefkis MJ, Dyck PJ, Plante-Bordeneuve V, Berk JL, Barroso F, Merlini G, Conceição I, Hughes SG, Kwoh J, Jung SW, Guthrie S, Pollock M, Benson MD, Gertz M; NEURO-TTR open-label extension investigators. Brannagan TH, et al. Among authors: berk jl. Eur J Neurol. 2020 Aug;27(8):1374-1381. doi: 10.1111/ene.14285. Epub 2020 May 29. Eur J Neurol. 2020. PMID: 32343462 Free PMC article. Clinical Trial.
147 results